SGLT2 inhibitors for non-diabetic kidney disease

Sodium-glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal E...

Descripción completa

Detalles Bibliográficos
Autores: Fernández-Fernández, Beatriz, Sarafidis, Pantelis|||0000-0002-9174-4018, Kanbay, Mehmet|||0000-0002-1297-0675, Navarro-González, Juan F.|||0000-0002-5015-7474, Soler, María José|||0000-0003-3621-0766, Górriz, Jose Luis|||0000-0002-1134-9051, Ortiz, Alberto|||0000-0002-9805-9523
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:238626
Acceso en línea:https://ddd.uab.cat/record/238626
https://dx.doi.org/urn:doi:10.1093/ckj/sfaa198
Access Level:acceso abierto
Palabra clave:Chronic kidney disease
Clinical trials
Mortality
Outcomes
SGLT2 inhibitor
id ES_4cb0afa158ece17159ebfaee20d3e3cd
oai_identifier_str oai:ddd.uab.cat:238626
network_acronym_str ES
network_name_str España
repository_id_str
spelling SGLT2 inhibitors for non-diabetic kidney diseasedrugs to treat CKD that also improve glycaemiaFernández-Fernández, BeatrizSarafidis, Pantelis|||0000-0002-9174-4018Kanbay, Mehmet|||0000-0002-1297-0675Navarro-González, Juan F.|||0000-0002-5015-7474Soler, María José|||0000-0003-3621-0766Górriz, Jose Luis|||0000-0002-1134-9051Ortiz, Alberto|||0000-0002-9805-9523Chronic kidney diseaseClinical trialsMortalityOutcomesSGLT2 inhibitorSodium-glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) trial. A meta-analysis of DAPA-HF and EMPEROR-Reduced confirmed reductions in all-cause and CV death and the combined risk of CV death or worsening HF, as well as in the composite renal endpoint {hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.43-0.90]} without differences based on the presence of diabetes or baseline estimated glomerular filtration rate (eGFR). Moreover, the Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) showed that dapagliflozin as an add-on over renin-angiotensin system blockade in patients with chronic kidney disease (CKD; with or without T2DM) reduced the HR for the primary endpoint (time to the first occurrence of ≥50% eGFR decline, end-stage kidney disease or renal or CV death) to 0.61 (95% CI 0.51-0.72) and for the secondary endpoints of worsening renal function or death from kidney failure [HR 0.56 (95% CI 0.45-0.68)], hospitalization for HF or CV death [HR 0.71 (95% CI 0.55-0.92)] and all-cause mortality [HR 0.69 (95% CI 0.53-0.88)]. These beneficial effects were consistent in patients with and without T2DM. In conclusion, SGLT2 inhibitors offer CV and kidney protection in both diabetic and non-diabetic CKD and, additionally, improve glycaemic control in T2DM, making them first-line therapy for CKD independent from diabetic status.Universitat Autònoma de Barcelona 22020-01-0120202020-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/238626https://dx.doi.org/urn:doi:10.1093/ckj/sfaa198reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI17/00257Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/01386Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19/00588Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19/00815Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 DTS18/00032Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 AC18/00064Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 AC18/00071Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD016/0009open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2386262026-06-06T12:50:31Z
dc.title.none.fl_str_mv SGLT2 inhibitors for non-diabetic kidney disease
drugs to treat CKD that also improve glycaemia
title SGLT2 inhibitors for non-diabetic kidney disease
spellingShingle SGLT2 inhibitors for non-diabetic kidney disease
Fernández-Fernández, Beatriz
Chronic kidney disease
Clinical trials
Mortality
Outcomes
SGLT2 inhibitor
title_short SGLT2 inhibitors for non-diabetic kidney disease
title_full SGLT2 inhibitors for non-diabetic kidney disease
title_fullStr SGLT2 inhibitors for non-diabetic kidney disease
title_full_unstemmed SGLT2 inhibitors for non-diabetic kidney disease
title_sort SGLT2 inhibitors for non-diabetic kidney disease
dc.creator.none.fl_str_mv Fernández-Fernández, Beatriz
Sarafidis, Pantelis|||0000-0002-9174-4018
Kanbay, Mehmet|||0000-0002-1297-0675
Navarro-González, Juan F.|||0000-0002-5015-7474
Soler, María José|||0000-0003-3621-0766
Górriz, Jose Luis|||0000-0002-1134-9051
Ortiz, Alberto|||0000-0002-9805-9523
author Fernández-Fernández, Beatriz
author_facet Fernández-Fernández, Beatriz
Sarafidis, Pantelis|||0000-0002-9174-4018
Kanbay, Mehmet|||0000-0002-1297-0675
Navarro-González, Juan F.|||0000-0002-5015-7474
Soler, María José|||0000-0003-3621-0766
Górriz, Jose Luis|||0000-0002-1134-9051
Ortiz, Alberto|||0000-0002-9805-9523
author_role author
author2 Sarafidis, Pantelis|||0000-0002-9174-4018
Kanbay, Mehmet|||0000-0002-1297-0675
Navarro-González, Juan F.|||0000-0002-5015-7474
Soler, María José|||0000-0003-3621-0766
Górriz, Jose Luis|||0000-0002-1134-9051
Ortiz, Alberto|||0000-0002-9805-9523
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Chronic kidney disease
Clinical trials
Mortality
Outcomes
SGLT2 inhibitor
topic Chronic kidney disease
Clinical trials
Mortality
Outcomes
SGLT2 inhibitor
description Sodium-glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) trial. A meta-analysis of DAPA-HF and EMPEROR-Reduced confirmed reductions in all-cause and CV death and the combined risk of CV death or worsening HF, as well as in the composite renal endpoint {hazard ratio [HR] 0.62 [95% confidence interval (CI) 0.43-0.90]} without differences based on the presence of diabetes or baseline estimated glomerular filtration rate (eGFR). Moreover, the Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (DAPA-CKD) showed that dapagliflozin as an add-on over renin-angiotensin system blockade in patients with chronic kidney disease (CKD; with or without T2DM) reduced the HR for the primary endpoint (time to the first occurrence of ≥50% eGFR decline, end-stage kidney disease or renal or CV death) to 0.61 (95% CI 0.51-0.72) and for the secondary endpoints of worsening renal function or death from kidney failure [HR 0.56 (95% CI 0.45-0.68)], hospitalization for HF or CV death [HR 0.71 (95% CI 0.55-0.92)] and all-cause mortality [HR 0.69 (95% CI 0.53-0.88)]. These beneficial effects were consistent in patients with and without T2DM. In conclusion, SGLT2 inhibitors offer CV and kidney protection in both diabetic and non-diabetic CKD and, additionally, improve glycaemic control in T2DM, making them first-line therapy for CKD independent from diabetic status.
publishDate 2020
dc.date.none.fl_str_mv 2
2020-01-01
2020
2020-01-01
dc.type.none.fl_str_mv Article de revisió
http://purl.org/coar/resource_type/c_dcae04bc
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/238626
https://dx.doi.org/urn:doi:10.1093/ckj/sfaa198
url https://ddd.uab.cat/record/238626
https://dx.doi.org/urn:doi:10.1093/ckj/sfaa198
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI17/00257
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18/01386
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19/00588
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI19/00815
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 DTS18/00032
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 AC18/00064
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 AC18/00071
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 RD016/0009
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407643730182144
score 15.811543

Similares en LA Referencia